Maze Therapeutics, Inc. cash flow to debt ratio of -480.31% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Maze Therapeutics, Inc.'s free cash flow has decreased 250.70% from $74.81M last year to $-112.73M, signaling decreasing performance

Maze Therapeutics, Inc.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability.

Maze Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.14 last year to 0.18 today, signaling weakened financials

Maze Therapeutics, Inc. has a net cash position, so leverage is healthy.

Maze Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Maze Therapeutics, Inc.'s profit margin has decreased (2.06K%) in the last year from 31.18% to -612.71%, signaling decreasing performance

Maze Therapeutics, Inc.'s short-term assets of $349.72M exceed its short-term liabilities of $22.56M

Maze Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Maze Therapeutics, Inc.'s return on equity of -36.63%, is lower than 15.00%, indicating bad performance

Maze Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Maze Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Maze Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Maze Therapeutics, Inc. has negative free cash flow, indicating cash burn

Maze Therapeutics, Inc.'s yearly earnings has decreased 351.04% since last year from $52.23M to $-131.12M, signaling decreasing performance

Maze Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $167.50M to $0.00, signaling decreasing performance

ROIC -33.24% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Maze Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Maze Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Maze Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Maze Therapeutics, Inc. has insufficient data to evaluate this check.

Maze Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Maze Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Maze Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Maze Therapeutics, Inc. has insufficient data to evaluate this check.

Maze Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Maze Therapeutics, Inc. has a price-to-book ratio of 4.30x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Maze Therapeutics, Inc. has a price-to-sales ratio of 73.51x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue